Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Immunol.

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1648156

Correction: Clinical outcomes of newly diagnosed PCNSL treated with rituximab-methotrexate-cytarabine with or without ibrutinib: a retrospective study

Provisionally accepted
Wenhua WangWenhua Wang1Bingyi WangBingyi Wang1Yifei SunYifei Sun1Lihua QiuLihua Qiu1Zhengzi QianZhengzi Qian1Shiyong ZhouShiyong Zhou1Zheng SongZheng Song1Wei LiWei Li1Xudong ZhangXudong Zhang2*Lanfang LiLanfang Li1*Xianhuo WangXianhuo Wang1*Huilai ZhangHuilai Zhang1*
  • 1Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
  • 2The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, China

This article is a correction to:

  1. Clinical outcomes of newly diagnosed PCNSL treated with rituximab-methotrexate-cytarabine with or without ibrutinib: A retrospective study

    1. Read original article

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

Name of all authors as they appear in the published original article (Wenhua Wang1,2†, Bingyi Wang1,2†, Yifei Sun1,2, Lihua Qiu1,2, Zhengzi Qian1,2, Shiyong Zhou1,2, Zheng Song1,2, Wei Li1,2, Xudong Zhang3*, Lanfang Li1,2*, Xianhuo Wang1,2* and Huilai Zhang1,2*) Affiliations of all authors as they appear in the published original version of the article (1State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin, China, 2Key Laboratory of Cancer Prevention and Therapy, The Sino-United States Center for Lymphoma and Leukemia Research, Tianjin, China, 3Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China) * Correspondence: Lanfang Li, lilanfangmeng@163.com; Xianhuo Wang, tjzlyy_xianhuow@163.com; Huilai Zhang, zhlwgq@126.com Keywords: central nervous system, lymphoma, ibrutinib, retrospective, methotrexate Correction on: Wang W, Wang B, Sun Y, Qiu L, Qian Z, Zhou S, Song Z, Li W, Li L, Wang X and Zhang H (2025) Clinical outcomes of newly diagnosed PCNSL treated with rituximab-methotrexate-cytarabine with or without ibrutinib: a retrospective study. Front. Immunol. 16:1579483. doi:10.3389/fimmu.2025.1579483

Keywords: Central Nervous System, Lymphoma, Ibrutinib, Retrospective, Methotrexate

Received: 16 Jun 2025; Accepted: 28 Aug 2025.

Copyright: © 2025 Wang, Wang, Sun, Qiu, Qian, Zhou, Song, Li, Zhang, Li, Wang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Xudong Zhang, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Lanfang Li, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Xianhuo Wang, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Huilai Zhang, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material